We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+7.88%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4B
AUM Growth
-$191M
(-4.5%)
Cap. Flow
-$236M
Cap. Flow
% of AUM
-5.9%
Top 10 Holdings %
Top 10 Hldgs %
48.84%
Holding
128
New
18
Increased
19
Reduced
24
Closed
26
Avg Time Held Equity + Options
10
quarters
Top 10 Avg Time Held Equity + Options
6.8
quarters
Top 20 Avg Time Held Equity + Options
6.6
quarters
Avg Time Held Equity only
10.6
quarters
Top 10 Avg Time Held Equity only
6.8
quarters
Top 20 Avg Time Held Equity only
6.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Caris Life Sciences
CAI
|
+$81.8M |
| 2 |
UnitedHealth
UNH
|
+$51.6M |
| 3 |
Roivant Sciences
ROIV
|
+$30.1M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$23.2M |
| 5 |
Jade Biosciences
JBIO
|
+$18.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$97.6M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$76.6M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$56.9M |
| 4 |
SpringWorks Therapeutics
SWTX
|
+$41.9M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$34.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.99% |
| 2 | Miscellaneous | 1.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Keros Therapeutics
KROS
$223M
| $13.6M | 0.34% |
1,018,734
| – | – |
2020 Q2
20 quarters
|
|
52
DELISTED
RAPT Therapeutics
RAPT
| $13.1M | 0.33% |
1,641,906
-2
| -0% | -$15 |
2024 Q4
2 quarters
|
|
53
DELISTED
Amicus Therapeutics
FOLD
| $13.1M | 0.33% |
2,285,400
| – | – |
2023 Q4
6 quarters
|
|
54
Vir Biotechnology
VIR
$1.82B
| $12M | 0.3% |
2,380,715
+132,466
| +6% | +$710K |
2023 Q4
6 quarters
|
|
55
AbCellera Biologics
ABCL
$4.08B
| $11.5M | 0.29% |
3,344,568
-836,200
| -20% | -$2.08M |
2020 Q4
18 quarters
|
|
56
DELISTED
Akero Therapeutics
AKRO
| $11.3M | 0.28% |
211,300
+31,400
| +17% | +$1.43M |
2024 Q4
2 quarters
|
|
57
Mineralys Therapeutics
MLYS
$1.85B
| $10.3M | 0.26% |
+760,351
| New | +$11M |
2025 Q2
0 quarters
|
|
58
Dyne Therapeutics
DYN
$2.89B
| $9.82M | 0.25% |
1,031,400
+16,789
| +2% | +$185K |
2024 Q1
5 quarters
|
|
59
C4 Therapeutics
CCCC
$344M
| $9.77M | 0.24% |
6,830,300
| – | – |
2024 Q2
4 quarters
|
|
60
Oric Pharmaceuticals
ORIC
$1.19B
| $9.13M | 0.23% |
899,281
+199,281
| +28% | +$1.34M |
2025 Q1
1 quarter
|
|
61
DELISTED
Catalyst Pharmaceutical
CPRX
| $9.05M | 0.23% |
+416,900
| New | +$9.84M |
2025 Q2
0 quarters
|
|
62
Prelude Therapeutics
PRLD
$284M
| $8.83M | 0.22% |
10,909,256
| – | – |
2020 Q3
19 quarters
|
|
63
Corbus Pharmaceuticals
CRBP
$92.5M
| $8.09M | 0.2% |
1,172,287
| – | – |
2024 Q3
3 quarters
|
|
64
Zai Lab
ZLAB
$2.59B
| $8.08M | 0.2% |
+231,000
| New | +$7.59M |
2025 Q2
0 quarters
|
|
65
Tarsus Pharmaceuticals
TARS
$3.32B
| $8.02M | 0.2% |
197,900
-455,843
| -70% | -$20.5M |
2025 Q1
1 quarter
|
|
66
Whitehawk Therapeutics
WHWK
$173M
| $7.79M | 0.19% |
4,166,000
| – | – |
2025 Q1
1 quarter
|
|
67
Tyra Biosciences
TYRA
$1.29B
| $7.7M | 0.19% |
804,603
-948,228
| -54% | -$9.01M |
2024 Q1
5 quarters
|
|
68
CALL
AstraZeneca
AZN
$242B
| $6.99M | 0.17% |
+50,000
| New | +$7.01M |
2025 Q2
0 quarters
|
|
69
Adicet Bio
ACET
$48.8M
| $6.98M | 0.17% |
715,446
| – | – |
2018 Q1
29 quarters
|
|
70
DELISTED
iTeos Therapeutics
ITOS
| $6.98M | 0.17% |
+700,000
| New | +$5.64M |
2025 Q2
0 quarters
|
|
71
PMV Pharmaceuticals
PMVP
$71.6M
| $6.86M | 0.17% |
6,475,291
| – | – |
2020 Q3
19 quarters
|
|
72
UroGen Pharma
URGN
$1.86B
| $6.55M | 0.16% |
+478,400
| New | +$4.59M |
2025 Q2
0 quarters
|
|
73
Ascendis Pharma A/S
ASND
$14.7B
| $5.94M | 0.15% |
+34,400
| New | +$5.6M |
2025 Q2
0 quarters
|
|
74
Alumis Inc
ALMS
$854M
| $5.78M | 0.14% |
+1,926,423
| New | +$9.1M |
2025 Q2
0 quarters
|
|
|
75
Jade Biosciences
JBIO
$863M
| $5.31M | 0.13% |
+531,163
| New | +$18.1M |
2025 Q2
0 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q2 2025 Portfolio in Review
As of Q2 2025, OrbiMed held 128 positions worth $4B, down 4.5% from $4.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
OrbiMed withdrew a net $236M in Q2 2025, closing 26 positions and reducing 24 holdings. Its most notable exit was Pfizer, an estimated $97.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Caris Life Sciences worth $81.1M.
- OrbiMed's largest Q2 2025 buy was Caris Life Sciences: 3,034,858 shares worth $81.1M.
- OrbiMed added most to UnitedHealth in Q2 2025, an estimated $51.6M increase.
- OrbiMed's biggest Q2 2025 reduction was Neurocrine Biosciences, cutting an estimated $56.9M.
- OrbiMed fully exited Pfizer in Q2 2025, selling an estimated $97.6M.
- OrbiMed's ten largest holdings make up 49% of its $4B portfolio in Q2 2025.
- OrbiMed opened 18 new positions and closed 26 in Q2 2025.
- OrbiMed's portfolio value fell 4.5% quarter-over-quarter to $4B.
Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.